Howard Levy - Concepedia

Author

Howard Levy

University of New Mexico ORCID

Also Known As

H A Levy, H LEVY, H Levy, H Lévy, H. A. Levy, H. LEVY, H. Levy, H. Levy, MD, PhD, HOWARD A. LEVY, HOWARD LEVY

182

Publications

9.5K

Citations

H-Index

117

Concepts

All Affiliations

University of New Mexico University of the Witwatersrand Eli Lilly (United States)South African Institute for Medical Research

About

Howard Levy is an author at University of New Mexico specializing in medicine, sepsis, and critical care medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	38	3.1K
2	Health Sciences	3	3	46
3	Social Sciences	2	2	23
4	Engineering	1	1	15
5	Public Health	1	1	28

Howard Levy

Publications

8.6K

Citations

H-Index

Page 1

	Year	Citations
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death Edward Abraham, Pierre‐François Laterre, Rekha Garg, New England Journal of Medicine	2005	882
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis Steven M. Opal, Charles J. Fisher, Jean-François Dhainaut, Critical Care Medicine	1997	856
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Edward Abraham, Antonio Anzueto, Guillermo Gutiérrez, PubMed	1998	628
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial Simon Nadel, Brahm Goldstein, Mark D. Williams, The Lancet Severe SepsisPediatricsSepsisSepsis PhenotypingMulticentre Phase Iii	2007	499
Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock Edward Abraham, Antonio Anzueto, Guillermo Gutiérrez, The Lancet Blood TransfusionImmunologyInflammatory MarkerSepsisSepsis Phenotyping	1998	497
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation* Jean‐Louis Vincent, M Ramesh, David Ernest, Critical Care Medicine	2013	315
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis E. Wesley Ely, Pierre‐François Laterre, Derek C. Angus, Critical Care Medicine	2003	282
Drotrecogin Alfa (activated) Improves In-hospital and 90-day Survival in Patients With Severe Sepsis and Community-acquired Pneumoni Richard G. Wunderink, Sachin Yende, Pierre‐François Laterre, CHEST Journal Critical Care MedicineSevere SepsisClinical TherapeuticAcute CarePatient Safety	2003	246
Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study* Pierre‐François Laterre, Gary Garber, Howard Levy, Critical Care Medicine	2005	196
Elevated Plasma Concentrations of IL-6 and Elevated APACHE II Score Predict Acute Kidney Injury in Patients with Severe Sepsis Lakhmir S. Chawla, Michael G. Seneff, David R. Nelson, Clinical Journal of the American Society of Nephrology Acute Lung InjurySevere SepsisImmunologyInflammationTranslational Medicine	2006	193

Page 1